Blood-Based Biomarkers for Neurological Disorders

This white paper discusses blood-based biomarkers (BBBs) for neurological disorders, emphasizing their role in early detection, monitoring, and patient stratification. It outlines how BBBs provide a minimally invasive alternative to cerebrospinal fluid in neurological research. The document details case studies utilizing various proteomic technologies, including SomaScan, KREX, and CyTOF, to identify and validate biomarkers across different neurological conditions. It highlights significant findings, such as a 25-protein signature predictive of dementia risk and the identification of candidate proteins linked to Alzheimer's disease and other disorders. The paper also addresses the challenges faced in the development and implementation of BBBs in clinical practice. Furthermore, it presents insights into the immune response related to glioblastoma and autism spectrum disorder, showcasing the potential of antibody profiling as a diagnostic tool. Overall, the document emphasizes the transformative impact of high-throughput proteomic technologies in advancing the understanding and treatment of neurological disorders.